Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

30.09 -0.04 (-0.13%)
Streaming Delayed Price Updated: 3:06 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Genmab Stock Trading Lower On Monday?
Genmab reported a 50% response rate and durable results for Rina-S in advanced endometrial cancer, with manageable side effects and no major toxicities. 
Via Benzinga
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why Genmab Stock Popped on Friday
Two pundits raised their price targets on the company. 
Via The Motley Fool
Curious about the stocks that are showing activity after the closing bell on Friday?
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Analyst Expectations For Genmab's Future
 
Via Benzinga
Breaking Down Genmab: 4 Analysts Share Their Views
 
Via Benzinga
Why Genmab Stock Was Marching Higher Today
The company's latest asset purchase seems to be impressing analysts. 
Via The Motley Fool
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. 
Via Benzinga
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer. 
Via Investor's Business Daily
Topics Government
GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria
Discover GMAB, a biotech stock matching Peter Lynch's GARP strategy. It offers strong earnings growth, a low PEG ratio, and excellent financial health for long-term investors. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals
Genmab (GMAB) is a high-value biotech stock with a low P/E ratio, strong financial health, and robust profitability, making it a standout undervalued opportunity. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): An Affordable Growth Candidate in Biotechnology
Discover GENMAB A/S (GMAB), an affordable growth stock with strong revenue expansion, solid profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation
GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors
GENMAB A/S (NASDAQ:GMAB) offers strong earnings growth, high profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
Why Genmab Stock Smashed It on Monday
Via The Motley Fool
GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential
GENMAB A/S (NASDAQ:GMAB) is a strong growth stock with solid fundamentals and a promising technical breakout pattern, offering potential for investors seeking growth opportunities. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors
GENMAB A/S (NASDAQ:GMAB) offers strong growth, solid profitability, and attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors
GENMAB A/S (NASDAQ:GMAB) offers strong growth, profitability, and a reasonable valuation, making it a standout pick for GARP investors following Peter Lynch’s strategy. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.
GENMAB A/S -SP ADR is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:GMAB showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock
GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock 
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?.
Based on a technical and fundamental analysis of NASDAQ:GMAB we can say: GENMAB A/S -SP ADR (NASDAQ:GMAB), a strong growth stock, setting up for a breakout. 
Via Chartmill
Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)
Peter Lynch, one of the most successful investors of all time, focused on growth stocks with strong fundamentals and a business model that’s easy to understand. Let’s analyze whether GENMAB A/S -SP ADR... 
Via Chartmill
Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.
GENMAB A/S -SP ADR was identified as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize... 
Via Stocktwits
Topics Stocks
What Analysts Are Saying About Genmab Stock
 
Via Benzinga
Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?
Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is GENMAB A/S -SP ADR (NASDAQ:GMAB) one of those under-the-radar stocks that fits his legendary strategy? 
Via Chartmill
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy. 
Via Benzinga
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Large-cap stocks worst performers last week: TER, TTD, COIN, SAIL, GMAB, IBKR, DAL, ADBE, EXPE, HOOD, UAL, AAPL. Are they in your portfolio? 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.